Skip to main content

Table 3 Univariate analysis for overall survival according to limited- and extensive-stage

From: Survival impact of prophylactic cranial irradiation in small-cell lung cancer in the modern era of magnetic resonance imaging staging

Variables

Limited-stage

Extensive-stage

n (%)

2-Year rate (%)

P

n (%)

2-Year rate (%)

P

Age (years)a

 ≤ 68

55 (51)

40

0.043

61 (50)

18

0.007

 > 68

52 (49)

28

61 (50)

7

Gender

Male

91 (85)

31

0.095

104 (85)

12

0.766

Female

16 (15)

50

18 (15)

18

ECOG score

0‒1

76 (71)

41

0.223

82 (67)

15

 < 0.001

 ≥ 2

11 (10)

27

20 (16)

5

Ever-smoker

Yes

95 (89)

32

0.604

93 (76)

7

0.068

No

10 (9)

56

27 (22)

14

Body mass index (kg/m2)a

 ≥ 23.6

55 (51)

44

0.020

50 (41)

18

0.021

 < 23.6

43 (40)

21

64 (53)

10

No. of symptoms at diagnosis

0

27 (25)

48

0.040

26 (21)

23

0.255

 ≥ 1

80 (75)

29

96 (79)

10

Clinical T stage

T1‒2

44 (41)

41

0.038

27 (22)

15

0.777

T3‒4

41 (38)

29

69 (57)

12

Clinical N stage

N0‒1

20 (19)

50

0.036

5 (4)

60

0.066

N2‒3

85 (79)

30

109 (89)

11

Extrathoracic metastasis

No

   

32 (26)

19

0.147

Yes

   

90 (74)

10

Definitive treatment

Chemoradiotherapyb

57 (53)

44

 < 0.001

15 (12)

27

0.072

Chemotherapy

37 (35)

11

99 (81)

10

Othersc

13 (12)

54

8 (7)

13

PCI

Yes

26 (24)

50

0.018

17 (14)

12

0.336

No

81 (76)

29

105 (86)

13

Salvage treatment

Chemoradiotherapyb

15 (14)

47

0.649

18 (15)

44

 < 0.001

Chemotherapy

16 (15)

31

22 (18)

9

Othersc

10 (9)

40

12 (10)

17

No treatment

65 (61)

31

70 (57)

4

  1. aThe median value was used as the cutoff point
  2. bCases with concurrent or sequential chemoradiotherapy were included
  3. cPatients who received radiotherapy alone or surgery (± adjuvant therapy) were included
  4. ECOG, Eastern Cooperative Oncology Group; PCI, prophylactic cranial irradiation